View Older Stories View More Recent Stories

Oct 2, 2025 04:05PM Dyne Therapeutics Appoints Brian Posner to its Board of Directors
Oct 1, 2025 04:18PM Form 144 Sionna Therapeutics, Filed by: Atlas Venture Fund XI, L.P.
Oct 1, 2025 04:17PM Form 144 Sionna Therapeutics, Filed by: Atlas Venture Opportunity Fund II, L.P.
Sep 30, 2025 04:22PM Form 144 Sionna Therapeutics, Filed by: Atlas Venture Fund XI, L.P.
Sep 30, 2025 04:22PM Form 144 Sionna Therapeutics, Filed by: Atlas Venture Opportunity Fund II, L.P.
Sep 29, 2025 04:40PM Form 144 Sionna Therapeutics, Filed by: Atlas Venture Fund XI, L.P.
Sep 29, 2025 04:39PM Form 144 Sionna Therapeutics, Filed by: Atlas Venture Opportunity Fund II, L.P.
Sep 18, 2025 07:00AM K36 Therapeutics to Present New Preclinical Data Supporting Ongoing Phase 1 Clinical Trial of KTX-1001 at the 22nd Annual International Myeloma Society Meeting
Sep 16, 2025 07:00AM K36 Therapeutics Provides Clinical Update on KTX-1001 in Multiple Myeloma
Sep 9, 2025 03:30AM Pheon Therapeutics Bolsters Board of Directors with Oncology R&D Expert Dr. Samuel Blackman
Sep 5, 2025 08:01AM Hengrui Pharma licenses cardiac drug to Braveheart Bio for $75 million upfront
Sep 5, 2025 08:00AM Hengrui Pharma and Braveheart Bio Enter Exclusive License Agreement for Cardiac Myosin Inhibitor HRS-1893
Sep 4, 2025 07:00AM Atlas Venture Announces $400 Million Third Opportunity Fund
Sep 4, 2025 06:31AM Form D Atlas Venture Opportunit
Aug 26, 2025 06:02AM Form N-PX Atlas Venture Life Scien For: Jun 30
Aug 22, 2025 04:30PM Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Opportunity Fund I, L.P.
Aug 22, 2025 04:25PM Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Fund X, L.P.
Aug 15, 2025 07:17PM Form SCHEDULE 13D/A Disc Medicine, Inc. Filed by: Atlas Venture Fund X, L.P.
Aug 14, 2025 04:32PM Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Opportunity Fund I, L.P.
Aug 14, 2025 04:24PM Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Fund X, L.P.
Aug 13, 2025 04:26PM Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Opportunity Fund I, L.P.
Aug 13, 2025 04:24PM Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Fund X, L.P.
Aug 12, 2025 04:49PM Form 13F-HR Atlas Venture Life Scien For: Jun 30
Aug 7, 2025 05:12PM Form SCHEDULE 13D/A Vigil Neuroscience, Inc. Filed by: Atlas Venture Fund XII, L.P.
Aug 7, 2025 05:00PM Form 4 Vigil Neuroscience, Inc. For: Aug 05 Filed by: Atlas Venture Fund XII, L.P.
Aug 7, 2025 08:00AM K36 Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for KTX-2001 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Announces Clinical Trial Collaboration
Aug 5, 2025 04:32PM Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Opportunity Fund I, L.P.
Aug 5, 2025 04:25PM Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Fund X, L.P.
Jul 30, 2025 04:18PM Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Opportunity Fund I, L.P.
Jul 30, 2025 04:15PM Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Fund X, L.P.
Jul 30, 2025 08:00AM Be Bio Announces First Participant Dosed in BeCoMe-9 Trial of BE-101 in Hemophilia B
Jul 29, 2025 04:54PM Form SCHEDULE 13D/A ImageneBio, Inc. Filed by: Atlas Venture Fund X, L.P.
Jul 25, 2025 09:07AM Form 13F-NT Atlas Venture Associates For: Jun 30
Jul 25, 2025 09:04AM Form 13F-NT Atlas Venture Associates For: Jun 30
Jul 25, 2025 09:03AM Form 13F-NT Atlas Venture Fund VIII, For: Jun 30
Jul 25, 2025 09:00AM Form 13F-HR Atlas Venture Advisors, For: Jun 30
Jul 24, 2025 04:28PM Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Opportunity Fund I, L.P.
Jul 24, 2025 04:26PM Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Fund X, L.P.
Jul 23, 2025 04:30PM Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Opportunity Fund I, L.P.
Jul 23, 2025 04:26PM Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Fund X, L.P.
Jul 18, 2025 04:34PM Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Opportunity Fund I, L.P.
Jul 18, 2025 04:31PM Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Fund X, L.P.
Jul 10, 2025 06:30AM Renasant Bio Launches to Pioneer Next-Generation Disease-Modifying Small Molecule Treatments for ADPKD
Jun 25, 2025 05:37PM Form 144 Jade Biosciences, Inc. Filed by: Atlas Venture Fund XII, L.P.
Jun 25, 2025 05:32PM Form 144 Jade Biosciences, Inc. Filed by: Atlas Venture Associates XII, L.P.
Jun 24, 2025 05:03PM Form 144 Jade Biosciences, Inc. Filed by: Atlas Venture Fund XII, L.P.
Jun 24, 2025 04:59PM Form 144 Jade Biosciences, Inc. Filed by: Atlas Venture Associates XII, L.P.
Jun 11, 2025 08:41AM Lifordi Immunotherapeutics Presents Preclinical Data on Glucocorticoid Antibody Drug Conjugate LFD-200 to Treat Autoimmune and Inflammatory Diseases at EULAR 2025
Jun 10, 2025 08:00AM Antares Therapeutics Launches with $177 Million to Develop First-in-Class Precision Medicines for Cancer and Other Serious Diseases
Jun 6, 2025 06:30AM Rectify Pharma Presents Translational Data Demonstrating Improvements in Kidney Function and Reductions in Vascular Calcification at ERA 2025
View More Recent Stories View Older Stories